Wells Fargo & Company Hillstream Bio Pharma Inc. Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.19 - $0.42 $0 - $1	4 Added 5.71%	74 $0
Q2 2023 Aug 15, 2023	BUY	$0.34 - $1.09 $13 - $42	39 Added 125.81%	70 $0
Q4 2022 Feb 13, 2023	BUY	$0.32 - $0.61 $0 - $0	1 Added 3.33%	31 $0
Q3 2022 Nov 14, 2022	BUY	$0.78 - $1.48 $3 - $5	4 Added 15.38%	30 $0
Q2 2022 Aug 12, 2022	BUY	$0.67 - $1.51 $2 - $4	3 Added 13.04%	26 $0
Q1 2022 May 16, 2022	BUY	$1.16 - $4.1 $26 - $94	23 New	23 $0

Ticker HILS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,529,900
Market Cap $33.2M
Description
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.